Skip to main content
Figure 4 | Molecular Pain

Figure 4

From: The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy

Figure 4

The cannabilactone AM1710 suppresses chemotherapy-induced mechanical and cold allodynia through a CB 2 -specific mechanism. AM1710-induced suppressions of cisplatin- (A, C) and paclitaxel- (B, D) evoked mechanical (A, B) and cold (C, D) allodynia were blocked by the CB2 antagonist AM630 (3 mg/kg i.p.) but not the CB1 antagonist AM251 (3 mg/kg i.p.). Data are expressed as mean ± SEM (n = 5-6 per group). *** P < 0.001, ** P < 0.01, * P < 0.05 vs. DMSO vehicle, One-way ANOVA followed by Dunnett post hoc test. xxx P < 0.01, xx P < 0.01, xP < 0.05 vs. AM1710 (5 mg/kg i.p.), Bonferroni post hoc test. $ P < 0.05 vs. AM1710 (5 mg/kg i.p.), planned t-test. ### P < 0.001 vs. pre-cisplatin/paclitaxel baseline (BL), repeated measures ANOVA.

Back to article page